Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this chapter we have attempted to provide an overview of the TRAIL induced signaling, list of proteins frequently deregulated and modern approaches to strategically restore apoptosis in TRAIL-resistant breast cancers.
|
31456187 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
IMPLICATIONS: This study discovers a paradoxical role of c-MYC in promoting metastasis to the brain and in rendering brain-metastatic cells more susceptible to TRAIL, which suggests the existence of an Achilles' heel, thus providing a new therapeutic opportunity for breast cancer patients.
|
30266755 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we found that TRAIL could induce PARP-1 cleavage and apoptosis in colon cancer HCT116 cell, but HT-29 cell was not sensitive to TRAIL.
|
31558316 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the combination of 3-BP and TRAIL can be a promising therapeutic strategy for treatment of colon cancer.
|
31491344 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that the increased BECN1 accompanied by enhanced autophagy activity is responsible for the TRAIL resistance, and a combination of TRAIL with a PIK3C3-BECN1 inhibitor is a promising therapeutic approach for the treatment of colon cancer.
|
31092562 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Co-treatment of TRAIL with GW4064 synergistically inhibited colorectal cancer cell proliferation as compared with single treatments.
|
31561852 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer.
|
31075907 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have also highlighted recent reports on TRAIL-mediated pathways and molecularly distinct voltage-gated sodium channels in colorectal cancer.
|
30633978 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
[Corrigendum] Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK‑mediated DR5 regulation in colorectal cancer.
|
30864690 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study used Western blotting to evaluate the combination effects of SC and TRAIL in CRC, and determined the molecular mechanism underlying these effects.
|
31083595 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analyses of apoptotic signaling events revealed that pinoresinol enhanced the formation of TRAIL-mediated death-inducing signaling complex (DISC) and complete processing of procaspase-8 within the DISC in glioblastoma cells, in which caspase-8 was inactivated.
|
31534206 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that depletion of eIF5B sensitizes glioblastoma multiforme cells to TRAIL-induced apoptosis by a pathway involving caspases-8, -9, and -7, with no significant effect on cell cycle progression. eIF5B promotes evasion of apoptosis by promoting the translation of several IRES-containing mRNAs, encoding the antiapoptotic proteins XIAP, Bcl-xL, cIAP1, and c-FLIP<sub>S</sub>.
|
30670698 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apart from genetic changes in DR4-Ser424, we further classified various cancer cell lines originated from stomach, colon, lung, and glioblastoma according to their sensitivity to and receptor preference upon TRAIL death signaling and generated TRAIL-tolerant persister-derived DLD-1<sup>PER</sup> cells.
|
30987996 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our current findings show that these biologic delivery vehicles have high tumor tropism efficacy and expression TRAIL gene under the trigger of TGF-β-secreting GBMs, as well as avoid unspecific TRAIL secretion into normal brain tissue. hAMSC-SBE4-TRAIL inhibited the proliferation and induced apoptosis in experimental GBMs both in vitro and in vivo.
|
30867058 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
|
31319548 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability.
|
30642878 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We thus established the TRAIL resistance models on glioma by using the U87 and U251 cell lines (U87/R and U251/R).
|
31056533 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
IMPLICATIONS: This study discovers a paradoxical role of c-MYC in promoting metastasis to the brain and in rendering brain-metastatic cells more susceptible to TRAIL, which suggests the existence of an Achilles' heel, thus providing a new therapeutic opportunity for breast cancer patients.
|
30266755 |
2019 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines.
|
30870485 |
2019 |
Neuroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We established N-myc-downregulated IMR-32 cells using shRNA lentiviral particles targeting N-myc and examined the effect the N-myc inhibition on TRAIL susceptibility in human neuroblastoma IMR-32 cells expressing caspase-8.
|
30724400 |
2019 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
EFLDO sensitizes liver cancer cells to TNFSF10‑induced apoptosis in a p53‑dependent manner.
|
30896802 |
2019 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to look into the approaches for increasing the sensitivity of liver cancer stem cells (LCSCs) toward TRAIL.
|
30774424 |
2019 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our studies support an innovative application of available PARP inhibitors or new cytoplasmic PARP-1 antagonists to enhance TRAIL therapy for TRAIL-resistant pancreatic cancers.
|
30614530 |
2019 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> Starting from the BXPC3 cell line, we generated and profiled a TRAIL-resistant model of pancreatic cancer, testing the impact of the combined treatment <i>in vitro</i> with specific cytotoxicity and metabolic assays.
|
30809285 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1.
|
31828111 |
2019 |